Grant: Engage Grants Program
University of Manitoba
$25,000.00
Identification of iron oxide nanoparticle size and shape for the most effective anti-microbial/anti-biofilm activity
FY 2018-19
Summary
The rise in antibiotic resistance is a global health-care problem [WHO - Antimicrobial resistance: Global report*on surveillance 2014]. There is a critical need for new strategies to combat infections. Topical biocides are a*possible solution to many hospital-acquired infections as they may be applied directly to the point of infection*and have a broad spectrum of microbial targets. However, they are not target specific - cytotoxicity is a*problem. This challenge may be addressed by coating magnetic nanoparticles (MNPs) with a biocide, enabling*removal from the infection site using a magnet field, and controlling contact time. To enable this technology*requires detailed insight into coating-chemistry, the MNPs magnetism, and the size and shape of MNPs to use.*Bacterial biofilms also cause tremendous infection problems. Biofilms consist of a community of*microorganisms with an extracellular matrix, and can be very difficult to remove as standard antibiotics and*disinfectants poorly penetrate the biofilm to kill or inhibit pathogenic microorganisms. Biofilms are perpetually*present on medical devices and wounds, and are a source of persistent and recurrent infections. With Kane*Biotech, my group is tackling this ""biofilm problem"" using new MNPs my group develops to create new*technologies for biofilm eradication using static and dynamic magnetic fields with the MNPs. Kane Biotech is*a Canadian company focused on novel products that prevent and disperse bacterial biofilms. For over 15 years*Kane Biotech's R&D division has been developing new technologies and innovations leading to over 75*patents and patents pending in biotechnology focusing primarily on biofilms. Through this Engage Grant, with*Kane, together we will apply our MNP and biofilm eradication research to establish the appropriate size and*shape of nanoparticles necessary to make possible biofilm eradication. The nanoparticle technology developed*during this Engage Grant will be adopted into Kane's portfolio of human and animal health technologies to be*leveraged into new ways to address those areas' biofilm problem.
Program
Engage Grants Program
Recipient
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
531280-2018
Name nom
vanLierop, Johan
Department département
Physics and Astronomy
Organization id
19
Institution établissement
University of Manitoba
Province en
Manitoba
Province fr
Manitoba
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
3305
Research subject group en
Condensed matterphysics
Research subject group fr
Physique de la matière condensée
Research subject en
Magnetic properties and magnetic materials
Research subject fr
Propriétés magnétiques et matériaux magnétiques
Partie
1
Nb partie
1
Application title
Identification of iron oxide nanoparticle size and shape for the most effective anti-microbial/anti-biofilm activity
Keyword
NSERC
Application summary
The rise in antibiotic resistance is a global health-care problem [WHO - Antimicrobial resistance: Global report*on surveillance 2014]. There is a critical need for new strategies to combat infections. Topical biocides are a*possible solution to many hospital-acquired infections as they may be applied directly to the point of infection*and have a broad spectrum of microbial targets. However, they are not target specific - cytotoxicity is a*problem. This challenge may be addressed by coating magnetic nanoparticles (MNPs) with a biocide, enabling*removal from the infection site using a magnet field, and controlling contact time. To enable this technology*requires detailed insight into coating-chemistry, the MNPs magnetism, and the size and shape of MNPs to use.*Bacterial biofilms also cause tremendous infection problems. Biofilms consist of a community of*microorganisms with an extracellular matrix, and can be very difficult to remove as standard antibiotics and*disinfectants poorly penetrate the biofilm to kill or inhibit pathogenic microorganisms. Biofilms are perpetually*present on medical devices and wounds, and are a source of persistent and recurrent infections. With Kane*Biotech, my group is tackling this ""biofilm problem"" using new MNPs my group develops to create new*technologies for biofilm eradication using static and dynamic magnetic fields with the MNPs. Kane Biotech is*a Canadian company focused on novel products that prevent and disperse bacterial biofilms. For over 15 years*Kane Biotech's R&D division has been developing new technologies and innovations leading to over 75*patents and patents pending in biotechnology focusing primarily on biofilms. Through this Engage Grant, with*Kane, together we will apply our MNP and biofilm eradication research to establish the appropriate size and*shape of nanoparticles necessary to make possible biofilm eradication. The nanoparticle technology developed*during this Engage Grant will be adopted into Kane's portfolio of human and animal health technologies to be*leveraged into new ways to address those areas' biofilm problem.